EcoDrugPlus

Tyrosine-Protein Kinase Fyna-Like

Ensembl ID : ENSPLAG00000011208
Gene Symbol: LOC106937692
3 Cross references
191 Possible Orthologues:

Uncharacterized Loc106939421

Ensembl ID : ENSPLAG00000005714
Gene Symbol: LOC106939421
2 Cross references
155 Possible Orthologues:

Uncharacterized Loc106955741

Ensembl ID : ENSPLAG00000006127
Gene Symbol: LOC106955741
2 Cross references
193 Possible Orthologues:

Utrophin

Ensembl ID : ENSPLAG00000011888
Gene Symbol: UTRN
2 Cross references
269 Possible Orthologues:

Vascular Endothelial Growth Factor A

Ensembl ID : ENSPLAG00000011115
Gene Symbol: VEGFA
3 Cross references
201 Possible Orthologues:

Vascular Endothelial Growth Factor Receptor 1-Like

Ensembl ID : ENSPLAG00000021248
Gene Symbol: LOC106963482
3 Cross references
198 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSPLAG00000018552
Gene Symbol: VDR
3 Cross references
392 Possible Orthologues:

Vitamin K Epoxide Reductase Complex Subunit 1-Like Protein 1

Ensembl ID : ENSPLAG00000012645
Gene Symbol: LOC106939030
3 Cross references
190 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1c-Like

Ensembl ID : ENSPLAG00000005929
Gene Symbol: LOC106943542
3 Cross references
212 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1d-Like

Ensembl ID : ENSPLAG00000005514
Gene Symbol: LOC106945205
3 Cross references
211 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1f-Like

Ensembl ID : ENSPLAG00000021210
Gene Symbol: LOC106942295
3 Cross references
176 Possible Orthologues:

Voltage-Dependent N-Type Calcium Channel Subunit Alpha-1b-Like

Ensembl ID : ENSPLAG00000016434
Gene Symbol: LOC106951545
3 Cross references
219 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).